Skip to main content
Clinical Trials/ACTRN12605000231640
ACTRN12605000231640
Terminated
Phase 3

A clinical trial of dexmedetomidine or remifentanil sedation for awake fibreoptic intubation

Dr Sarah Harper0 sites20 target enrollmentAugust 26, 2005

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Sarah Harper
Enrollment
20
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 26, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr Sarah Harper

Eligibility Criteria

Inclusion Criteria

  • Awake fibreoptic intubation, no contraindication to remifentanil or dexmedetomidine.

Exclusion Criteria

  • Chronic alpha\-2 agonist or opioid therapy, allergy or previous adverse reaction to study drugs, uncontrolled hypertension, heart \<50, 2nd or 3rd degree heart block, severe ventricular, renal, hepatic or respiratory dysfuction, pregnancy or lactation.

Outcomes

Primary Outcomes

Not specified

Similar Trials